Significant Reduction in Gender Dysphoria, Depression, and Suicidality Observed
A recent study published in JAMA Network Open has shed light on the transformative impact of testosterone therapy on transgender and gender-diverse adults. The therapy has been found to significantly alleviate gender dysphoria, depression, and suicidality, marking a significant stride in transgender healthcare.
HCN Medical Memo
This study underscores the profound potential of testosterone therapy in improving the mental health outcomes of transgender and gender-diverse individuals. As healthcare professionals, it is crucial to advocate for timely access to gender-affirming hormone therapy to significantly enhance the quality of life for these individuals.
- The study was conducted by Brendan J. Nolan, M.B.B.S., from Austin Health in Heidelberg, Australia, and his team.
- The research involved 64 transgender and gender-diverse adults.
- Over a three-month trial period, the intervention group reported a decrease in gender dysphoria (mean difference, −7.2 points), a clinically significant decrease in depression (mean difference, −5.6 points on the Patient Health Questionnaire-9 [PHQ-9]), and a significant decrease in suicidality (mean difference score, −6.5 points on the Suicidal Ideation Attributes Scale).
- Among individuals with immediate testosterone commencement, resolution of suicidality assessed by PHQ-9 item 9 occurred in 52 percent of participants versus 5 percent with standard care.
According to the American Psychological Association, an estimated 0.6% of adults in the US identify as transgender.
- Two authors reported receiving products from Besins Healthcare for separate investigator-initiated clinical studies using estradiol and progesterone.
More on LGBTQIA+ Medicine